Cargando…

Antibody–drug conjugates as novel anti-cancer chemotherapeutics

Over the past couple of decades, antibody–drug conjugates (ADCs) have revolutionized the field of cancer chemotherapy. Unlike conventional treatments that damage healthy tissues upon dose escalation, ADCs utilize monoclonal antibodies (mAbs) to specifically bind tumour-associated target antigens and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peters, Christina, Brown, Stuart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2015
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613712/ https://www.ncbi.nlm.nih.gov/pubmed/26182432 http://dx.doi.org/10.1042/BSR20150089

Ejemplares similares

Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics
por: Kumari, Mamta, et al.
Publicado: (2023)

Research progress of anti-glioma chemotherapeutic drugs
por: Zhou, Yi-Shu, et al.
Publicado: (2022)

Novel development strategies and challenges for anti-Her2 antibody-drug conjugates
por: Zhang, Xinling, et al.
Publicado: (2022)

Antibody drug conjugates: hitting the mark in pancreatic cancer?
por: Wittwer, Nicole L., et al.
Publicado: (2023)

The anti-psychotic drug pimozide is a novel chemotherapeutic for breast cancer
por: Dakir, EL-Habib, et al.
Publicado: (2018)

Antibody-Drug Conjugates in Bladder Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2018)

Antibody–Drug Conjugates for Cancer Therapy
por: Parslow, Adam C., et al.
Publicado: (2016)

Antibody–Drug Conjugates for Cancer Therapy
por: Hafeez, Umbreen, et al.
Publicado: (2020)

Potential of antibody–drug conjugates and novel therapeutics in breast cancer management
por: Lianos, Georgios D, et al.
Publicado: (2014)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)

A novel strategy for treatment of bladder cancer: Antibody-drug conjugates
por: Kim, Jung Hoon, et al.
Publicado: (2022)

Anti-claudin-4 extracellular domain antibody enhances the antitumoral effects of chemotherapeutic and antibody drugs in colorectal cancer
por: Fujiwara-Tani, Rina, et al.
Publicado: (2018)

Flavonoids Synergistically Enhance the Anti-Glioblastoma Effects of Chemotherapeutic Drugs
por: Zhai, Kevin, et al.
Publicado: (2021)

Gold nanoparticles conjugated with anti-CD133 monoclonal antibody and 5-fluorouracil chemotherapeutic agent as nanocarriers for cancer cell targeting
por: Mohd-Zahid, Manali Haniti, et al.
Publicado: (2021)

Role of chemotherapeutic drugs in immunomodulation of cancer
por: Mukherjee, Oishi, et al.
Publicado: (2023)

Fate of Antibody-Drug Conjugates in Cancer Cells
por: Chalouni, Cécile, et al.
Publicado: (2018)

Treating Prostate Cancer by Antibody–Drug Conjugates
por: Rosellini, Matteo, et al.
Publicado: (2021)

Advances and Limitations of Antibody Drug Conjugates for Cancer
por: Mckertish, Candice Maria, et al.
Publicado: (2021)

Antibody–Drug Conjugates for the Treatment of Breast Cancer
por: Corti, Chiara, et al.
Publicado: (2021)

Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer
por: Manzano, Aranzazu, et al.
Publicado: (2020)

Safety and Tolerability of Antibody-Drug Conjugates in Cancer
por: Wolska-Washer, Anna, et al.
Publicado: (2019)

Antibody-Drug Conjugates Used in Breast Cancers
por: Abbas, Aram J., et al.
Publicado: (2021)

Introduction to Antibody-Drug Conjugates
por: Pettinato, Mark C.
Publicado: (2021)

Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy
por: Tamburrino, Anna, et al.
Publicado: (2013)

Antibody–drug conjugates, cancer immunotherapy, and metronomic chemotherapy as novel approaches in cancer management
por: Sarangi, Sudhir Chandra, et al.
Publicado: (2020)

Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody–Drug Conjugates for Cancer Therapy
por: Johan, Audrey Nathania, et al.
Publicado: (2022)

An energy-blocking nanoparticle decorated with anti-VEGF antibody to reverse chemotherapeutic drug resistance
por: Gu, Liu-Qing, et al.
Publicado: (2019)

Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations
por: Shim, Hyunbo
Publicado: (2020)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

Site-specific antibody drug conjugates for cancer therapy
por: Panowski, Siler, et al.
Publicado: (2013)

Targeting cancer with antibody-drug conjugates: Promises and challenges
por: Dean, Alexis Q., et al.
Publicado: (2021)

Potential of antibody–drug conjugates (ADCs) for cancer therapy
por: Marei, Hany E., et al.
Publicado: (2022)

Trends in the Development of Antibody-Drug Conjugates for Cancer Therapy
por: Song, Chi Hun, et al.
Publicado: (2023)

Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy
por: Wu, Mo, et al.
Publicado: (2022)

Antibody-drug conjugates: recent advances in conjugation and linker chemistries
por: Tsuchikama, Kyoji, et al.
Publicado: (2016)

Phospholipid prodrug conjugates of insoluble chemotherapeutic agents for ultrasound targeted drug delivery
por: Márquez, Mendi G., et al.
Publicado: (2020)

Antibody–drug conjugates in solid tumors: a look into novel targets
por: Criscitiello, Carmen, et al.
Publicado: (2021)

Acquired Resistance to Antibody-Drug Conjugates
por: Collins, Denis M., et al.
Publicado: (2019)

Antibody–Drug Conjugates: The Last Decade
por: Joubert, Nicolas, et al.
Publicado: (2020)

Clinical Pharmacology of Antibody-Drug Conjugates
por: Mahmood, Iftekhar
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tg6p646afu4vq5b68cjq3r1m47